secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-09-28T12:16:10+00:00
Accession:  0001104659-26-111170
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

TransCode's TTX-MC138 shows 71.4% stable disease in Phase 1a; no dose-limiting toxicities
--------------------------------------------------------------------------------

- 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as best overall response by investigator assessment; disease control was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
- Durability: 6 of 14 patients progression-free at 3 months, 3 at 6, 9 and 12 months; three efficacy-evaluable patients remain progression-free at one year.
- No dose-limiting toxicities at any dose including the highest evaluated 4.8 mg/kg; 98 doses administered as of the September 1, 2026 data cutoff; no treatment discontinuations.
- Post-hoc Growth Modulation Index: 6 of 15 evaluable patients (40%) had GMI above 1.3, meaning at least 30% longer progression-free interval than their prior therapy.
- Exploratory blood RNA-sequencing showed dose-dependent antitumor immune activation; TransCode is evaluating dose-expansion strategies in selected cancers and molecularly defined populations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926111170/0001104659-26-111170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926111170/tm2626237d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-111170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer